- D68.61 is a billable/specific ICD-10-CM code that can be used to indicate a diagnosis for reimbursement purposes.
- The 2024 edition of ICD-10-CM D68.61 became effective on October 1, 2022.
- This is the American ICD-10-CM version of D68.61 – other international versions of ICD-10 D68.61 may differ.
ICD-10-CM D68.61 is grouped within Diagnostic Related Group(s):
- 814 Reticuloendothelial and immunity disorders with mcc
- 815 Reticuloendothelial and immunity disorders with cc
- 816 Reticuloendothelial and immunity disorders without cc/mcc
Applicable To
- Anticardiolipin syndrome
- Antiphospholipid antibody syndrome
Type 1 Excludes
- anti-phospholipid antibody, finding without diagnosis (R76.0)
- anti-phospholipid antibody with hemorrhagic disorder (D68.312)
- lupus anticoagulant syndrome (D68.62)
Code History
- 2016 (effective 10/1/2015): New code (first year of non-draft ICD-10-CM)
- 2016 (effective 10/1/2015): No change
- 2017 (effective 10/1/2016): No change
- 2018 (effective 10/1/2017): No change
- 2019 (effective 10/1/2018): No change
- 2020 (effective 10/1/2019): No change
- 2021 (effective 10/1/2020): No change
- 2022 (effective 10/1/2021): No change
- 2024 (effective 10/1/2022): No change
Diagnosis Index entries containing back-references to D68.61:
- hypercoagulable state > with D68.312
- hypercoagulable state > with D68.312
- hypercoagulable state > with D68.312
- hypercoagulable state > with D68.312
- hypercoagulable state > with D68.312
- syndrome > antibody D68.312
- anticardiolipin (-antibody) > Syndrome
- antiphospholipid (-antibody) > Syndrome